bempegaldesleukin,nivolumab
bms,nektar
['bms', 'nektar']
more than four years after bms proudly unveiled a $3.6 billion, next-gen i/o alliance with nektar, including about half of that in cash, investigators have turned up at #esmo22 with the full set of disastrous phase iii data that helped ice the whole deal. 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs